BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1333 trials with phase data)• Click on a phase to view related trials
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
- Conditions
- Advanced Melanoma
- Interventions
- Biological: Immunotherapy monotherapyDrug: BRAF/MEK inhibitors
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 678
- Registration Number
- NCT07079644
- Locations
- 🇺🇸
Bristol Myers Squibb, Princeton, New Jersey, United States
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT07077434
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-07-21
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 470
- Registration Number
- NCT07076121
- Locations
- 🇺🇸
Local Institution - 0142, Phoenix, Arizona, United States
🇺🇸Local Institution - 0306, Springdale, Arkansas, United States
🇺🇸Local Institution - 0157, San Francisco, California, United States
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 250
- Registration Number
- NCT07075406
- Locations
- 🇺🇸
RTI Health Solutions, Research Triangle Park, North Carolina, United States
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT07073690
- Locations
- 🇨🇳
Zhijian Xiao, Tianjin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 297
- Next
News
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
Dispatch Bio Emerges with $216M to Develop Universal Solid Tumor Immunotherapy
Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Bristol Myers Squibb's Reblozyl Fails Primary Endpoint in Phase III Myelofibrosis Trial Despite Secondary Benefits
Bristol Myers Squibb's anemia drug Reblozyl failed to meet its primary endpoint of red blood cell transfusion independence in the Phase III INDEPENDENCE trial for myelofibrosis patients.
FDA Advisory Panel Rejects GSK's Blenrep Combination Therapies for Multiple Myeloma
FDA advisers voted 5-3 against approving GSK's Blenrep in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma patients.
Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount
Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.
FDA Raises Eye Safety Concerns for GSK's Blenrep Ahead of Advisory Committee Review
The FDA has identified significant ocular toxicity concerns with GSK's Blenrep (belantamab mafodotin) ahead of a July 17 advisory committee meeting to review the drug's reintroduction to the U.S. market.
Insurance Disparities Widen Cancer Survival Gaps Despite Immune Checkpoint Inhibitor Advances
A new American Cancer Society study reveals that immune checkpoint inhibitors, while improving survival across all insurance groups, have widened survival disparities between uninsured patients and those with private insurance for advanced melanoma, lung, and kidney cancers.
AbbVie Acquires In Vivo CAR-T Developer Capstan Therapeutics for Up to $2.1 Billion
AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.
FDA Removes Regulatory Barriers for Bristol Myers Squibb's CAR T-Cell Therapies, Expanding Patient Access
The FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) programs and reduced post-treatment monitoring from four weeks to two weeks for Bristol Myers Squibb's CAR T-cell therapies Breyanzi and Abecma.